13
Views
9
CrossRef citations to date
0
Altmetric
Review

High-risk basal cell carcinoma: an update

, , , , , & show all
Pages 357-368 | Published online: 10 Jan 2014
 

Abstract

High-risk basal cell carcinoma (BCC) is an aggressive malignant tumor of the skin, with a potential of perineural, lymphatic and vascular spreading. This review presents the most common types and anatomical sites of high-risk BCC, and evaluates the diagnosis, clinical presentation and treatment options available. Based on the current data, micrographically controlled (Mohs) surgery or frozen section controlled excision is the treatment of choice. In cases with impossible complete tumor resection, radiotherapy is an alternative. In patients with a high risk of recurrence, adjuvant radiotherapy is used. Medical treatment of high-risk BCC is rather limited. Metastatic BCC have been treated with cisplatin-based chemotherapy. Chemo-immunotherapy, monoclonal antibodies and electrochemotherapy have been used more recently, but only case reports have been published. There is a need for controlled clinical trials. Regular follow-up is necessary in patients with high-risk BCC, but as yet no international consensus has been achieved. The German Dermatologic Society recommends 5 years of follow-up for all BCC patients.

Acknowledgements

We wish to thank B Reitemeier (University Hospital, Technical University of Dresden) for providing.

Financial & competing interests disclosure

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

No writing assistance was utilized in the production of this manuscript.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.